A Look At Liquidia (LQDA) Valuation After YUTREPIA Fueled Profitability And Strong First Quarter Results

Liquidia (LQDA) is back on investors’ radar after first quarter 2026 results showed revenue of US$132.87 million and net income of US$52.86 million, supported by strong uptake of pulmonary ...

How Liquidia’s Swing to Profit in Q1 2026 At Liquidia (LQDA) Has Changed Its Investment Story

Liquidia Corporation recently reported its first quarter 2026 results, with revenue rising to US$132.87 million from US$3.12 million a year earlier and net income reaching US$52.86 million versus a ...
Healio

FDA grants Yutrepia final approval for PAH, PH-ILD

Please provide your email address to receive an email when new articles are posted on . Liquidia Corporation received final FDA approval for Yutrepia for the treatment of PAH and PH-ILD. The company ...

Liquidia (LQDA) Hits All-Time High as Yutrepia Drives Swing to Profits

Liquidia climbed to a fresh all-time high on Monday, as investors took heart from its stellar earnings performance in the first quarter of the year, thanks to strong sales from its pulmonary ...
Monthly Prescribing Reference

Yutrepia Gets Tentative Approval for Pulmonary Arterial Hypertension

PAH, pulmonary hypertension, pulmonary arterial hypertension, CTEPH Yutrepia is an inhaled dry powder formulation of tresprostinil delivered through a palm-sized device. The Food and Drug ...
Seeking Alpha

Liquidia: Yutrepia's Launch Momentum Is Approaching A Ceiling (Rating Downgrade)

Liquidia delivered strong Q1 results, with Yutrepia net sales up 44% sequentially and a third consecutive profitable quarter. LQDA now commands a 23% share of the inhaled prostacyclin segment, but ...
Healio

FDA has yet to confirm Yutrepia for pulmonary hypertension-ILD

Please provide your email address to receive an email when new articles are posted on . The FDA did not meet its Prescription Drug User Fee Act goal date that would extend Yutrepia as a treatment for ...
Nasdaq

Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia

Shares of Liquidia Corporation LQDA lost nearly 31% on Monday after the FDA delayed granting full approval to its Yutrepia (treprostinil) inhalation powder in a pair of lung disorder indications. The ...
Benzinga.com

Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge

On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation’s (NASDAQ:LQDA) Yutrepia (treprostinil) inhalation powder, a prostacyclin analog for adults with pulmonary arterial ...
Hosted on MSN

Liquidia stock gains premarket on Q4 revenue beat – investors are betting on YUTREPIA growth

Liquidia Corp. (LQDA) on Thursday released its financial results for the fourth quarter (Q4), highlighting strong early traction in the commercial rollout of its respiratory drug, YUTREPIA. The ...
manilatimes

U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with ...

FDA's approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILD YUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device ...